Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Hikma trims full year revenue forecast on Advair U.S. launch delay

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/19/2017 | 09:32am CEST

(Reuters) - Drugmaker Hikma Pharmaceuticals Plc on Friday lowered its revenue forecast for the full year to reflect a delay in the launch of its generic asthma drug, after U.S. regulators denied approval citing "major" issues with the application.

Shares of the company fell as much 7.47 percent to 1,573 pence, the lowest since May, 2014. They were the top loser on the FTSE 100 bluechip index and the pan-European Stoxx 600 index.

Hikma now expects full-year revenue to be in the range of $2.0 billion-$2.1 billion at constant currency, down from its earlier forecast of $2.2 billion (1.7 billion pounds).

Earlier this month, the company said approval for its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair was unlikely in 2017.

Hikma and its partner Vectura Group Plc are in a race with Mylan to launch the first U.S. generic copy of Advair. The FDA has already delayed approval of Mylan's version.

Hikma on Friday lowered its 2017 revenue forecast for its generics business to $670 million, down from its earlier forecast of $800 million.

"This assumes we do not launch our generic version of Advair Diskus in 2017 and reflects the intensifying competitive environment in the U.S.," the company said in a statement.

Hikma maintained its full-year revenue estimate for its injectables unit at a range of $800 million-$825 million, with core operating margin seen in the high 30s.

(Reporting by Sanjeeban Sarkar and Tenzin Pema in Bengaluru; Editing by Sunil Nair)

Stocks mentioned in the article
ChangeLast1st jan.
FTSE 100 INDEX 0.28% 7234.11 End-of-day quote.-5.90%
HIKMA PHARMACEUTICALS 1.98% 1208 Delayed Quote.6.53%
MYLAN NV -0.22% 40.72 Delayed Quote.-3.55%
STOXX EUR 600(P)-EUR -0.03% 381.84 End-of-day quote.-1.88%
VECTURA GROUP PLC -6.26% 98.05 Delayed Quote.-16.70%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
04/20LONDON MARKETS : FTSE 100 Ends At 11-week High As Pound Falls On BOE Rate-hike D..
DJ
04/20P&G's vitamin boost could signal more to come
RE
04/19GLAXOSMITHKLINE : New Gingivitis Study Results from GlaxoSmithKline plc Describe..
AQ
04/19GLAXOSMITHKLINE : An Application for the Trademark "DOVATOR" Has Been Filed by G..
AQ
04/19GLAXOSMITHKLINE : Trademark Application for "DOVIPSA" Filed
AQ
04/19GLAXOSMITHKLINE : Trademark Application for "ABREVA" Filed by GlaxoSmithKline
AQ
04/19GLAXOSMITHKLINE : Reports Summarize Vaccines Study Results from GlaxoSmithKline ..
AQ
04/19GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Describe Findings in Tube..
AQ
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/19NEUROMETRIX : Reports Q1 2018 Financial Results
AQ
More news
News from SeekingAlpha
04/21STOCKS TO WATCH : Earnings Blockbusters And Trump Talks Drug Prices 
04/19Novartis Q1 results weigh on pharma stocks 
04/18Glaxo poaches Roche dealmaker signaling commitment to pipeline-boosting trans.. 
04/17Evelo Biosciences Files For U.S. IPO 
04/17JF'S CORE BIOTECH BUYS #11 : Positive News For Several Holdings, A Change To Ben.. 
Financials ( GBP)
Sales 2018 29 850 M
EBIT 2018 8 139 M
Net income 2018 3 877 M
Debt 2018 17 446 M
Yield 2018 5,60%
P/E ratio 2018 17,65
P/E ratio 2019 15,24
EV / Sales 2018 2,96x
EV / Sales 2019 2,85x
Capitalization 70 913 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 15,4  GBP
Spread / Average Target 7,9%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE8.13%99 256
JOHNSON & JOHNSON-8.71%339 783
PFIZER0.86%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571